Aurobindo Pharma Unit IV Clears US FDA Inspection With VAI

Aurobindo Pharma has announced that the US FDA VAI classification has been granted to an API manufacturing facility operated by its wholly owned subsidiary, Apitoria Pharma Private Limited.

The update follows a regulatory inspection by the U.S. Food and Drug Administration (US FDA) at the company’s manufacturing site in Telangana.

The inspection was conducted at the active pharmaceutical ingredient (API) facility located in Pashamylaram Village between December 9 and December 17, 2024. After reviewing the findings, the regulator categorized the inspection outcome as Voluntary Action Indicated (VAI), indicating that while certain observations were made, they do not require any immediate regulatory enforcement action.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

The US FDA VAI classification typically means that inspectors identified minor compliance issues during the inspection. However, these observations are not considered serious enough to trigger official regulatory measures such as warning letters or import restrictions. Instead, the company is expected to address the observations through voluntary corrective actions.

Aurobindo Pharma said it has now received the Establishment Inspection Report (EIR) from the US regulator confirming the VAI status for the facility. The EIR formally closes the inspection process and signals that the regulator is satisfied with the overall compliance status of the manufacturing unit.

The development is important for the company as regulatory compliance with the US FDA remains critical for Indian pharmaceutical firms that export medicines to the United States. Facilities that maintain acceptable inspection outcomes can continue supplying products to the global market without regulatory disruption.

Investors and industry watchers will continue to track regulatory updates from Aurobindo Pharma’s manufacturing network, as FDA inspection outcomes often influence operations, product approvals, and export momentum for pharmaceutical companies.